Currently, 40% of all NMFC items fall within the scope of review. That represents more than 5,000 potential changes. The final docket for phase one (docket 2025-1) will be released on Jan. 30 with a ...

Scholar Rock has a promising SMA treatment. Apitegromab's unique approach targets precursor myostatin. See why SRRK stock is ...

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating ...

The Company has received approval to begin enrollment of the Phase 1b clinical trial in AustraliaPhase 1b clinical trial will assess safety and ...

Japanese automakers Honda and Nissan have announced plans to join forces, forming world’s third-largest automaker by sales as ...

A Japanese space startup said its second attempt to launch a rocket carrying small satellites into orbit had been terminated ...

Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and ...

NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...

In 2024, permanent magnet motors installations have ballooned to 11% of electric submersible pump installations, and that ...

The reduced expectations for 2025 rate cuts sent Treasury yields rising in the bond market, ramping up the pressure on the ...